Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination

• Published in: Nature medicine Vol. 28; no. 3; pp. 486 - 489
• Main Authors: Cheng, Samuel M. S., Mok, Chris Ka Pun, Leung, Yonna W. Y., Ng, Susanna S., Chan, Karl C. K., Ko, Fanny W., Chen, Chunke, Yiu, Karen, Lam, Bosco H. S., Lau, Eric H. Y., Chan, Ken K. P., Luk, Leo L. H., Li, John K. C., Tsang, Leo C. H., Poon, Leo L. M., Hui, David S. C., Peiris, Malik
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.03.2022; Nature Publishing Group
• Subjects: 631/250/2152/2153/1291; 631/250/590/1883; 631/250/590/2293; 631/326/596/4130; 692/699/255/2514; Antibodies; Antibodies, Neutralizing; Antibodies, Viral; Biomedical and Life Sciences; Biomedicine; BNT162 Vaccine; Brief Communication; Cancer Research; COVID-19; COVID-19 - prevention & control; COVID-19 vaccines; Homology; Humans; Infectious Diseases; Metabolic Diseases; Molecular Medicine; mRNA; mRNA Vaccines; Neurosciences; Neutralization; Neutralizing; SARS-CoV-2 - genetics; Severe acute respiratory syndrome coronavirus 2; Vaccination; Vaccines; Vaccines, Synthetic; Viral diseases; Viruses

The Omicron variant is rapidly becoming the dominant SARS-CoV-2 virus circulating globally. It is important to define reductions in virus neutralizing activity in the serum of convalescent or vaccinated individuals to understand potential loss of protection against infection by Omicron. We previousl...